FY2024 EPS Estimates for Vivani Medical Lowered by Analyst

Vivani Medical, Inc. (NASDAQ:VANI - Free Report) - Equities research analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for Vivani Medical in a research note issued to investors on Thursday, March 13th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.43) per share for the year, down from their previous forecast of ($0.41). HC Wainwright currently has a "Buy" rating and a $4.00 target price on the stock. The consensus estimate for Vivani Medical's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Vivani Medical's Q1 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.39) EPS.

Vivani Medical Trading Down 0.5 %

VANI stock traded down $0.01 during trading on Monday, hitting $1.10. The company had a trading volume of 28,363 shares, compared to its average volume of 176,110. The business has a 50-day moving average of $1.15 and a 200-day moving average of $1.22. Vivani Medical has a one year low of $1.03 and a one year high of $2.22. The stock has a market cap of $64.86 million, a PE ratio of -2.43 and a beta of 3.20.

Institutional Trading of Vivani Medical

Several institutional investors have recently added to or reduced their stakes in the stock. Wealthedge Investment Advisors LLC bought a new stake in Vivani Medical in the fourth quarter valued at approximately $43,000. Jane Street Group LLC bought a new stake in Vivani Medical in the fourth quarter valued at approximately $66,000. Northern Trust Corp boosted its holdings in Vivani Medical by 19.1% in the fourth quarter. Northern Trust Corp now owns 71,915 shares of the company's stock valued at $83,000 after acquiring an additional 11,540 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Vivani Medical by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 342,891 shares of the company's stock worth $401,000 after buying an additional 15,008 shares in the last quarter. 6.78% of the stock is currently owned by institutional investors.

Remove Ads

About Vivani Medical

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.